Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis partners again with Xoma; this time licensing gevokizumab and IL-1 beta IP for CV indications

Executive Summary

Xoma Corp. licensed Novartis AG exclusive worldwide rights to gevokizumab (XOMA052), an anti-interleukin-1 beta (IL-1b) allosteric monoclonal antibody. Novartis also secured nonexclusive rights to Xoma's intellectual property related to IL-1b-targeting antibodies in cardiovascular disease.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies